Skip to main content
Home > BC Innovations > Strategy

Chronological Index of : Strategy

 Current Issue
  • Mapping non-sense

    Epigenomics reference standard based on signatures from 111 different cell types

    The NIH Roadmap Epigenomics Mapping Consortium's bank of epigenomic signatures from over 100 cell types is only the first step on a very long road to filling the gaps between genes and disease.

    Published on 3/12/2015
  • Adding Up for AD

    Stakeholders are optimistic that Alzheimer's disease funding is on the rise

    NIH's meeting with G7 health leaders coincided with three announcements about AD funding, and stakeholders are optimistic the field is starting to get some much-needed attention.

    Published on 3/5/2015
  • Cardio reboot

    Why Philip Sager thinks better preclinical tools can spur drug development

    Cardiologist Philip Sager says the current thinking on preclinical cardiovascular safety involves new ways of looking at ion conductance to replace QT, and might enable or rescue many compounds.

    Published on 3/5/2015
  • NIH: newer, not younger

    How NIH's Sally Rockey wants to increase flux in academia

    NIH's Sally Rockey is concerned about the U.S. losing its innovation edge, and outlines ways to keep young researchers invested and involved in the system.

    Published on 2/5/2015
  • European mediation

    New formats for PPPs to drive translational medicine in Europe

    TRON and TI Pharma are hoping to disrupt European translation with new models of public-private partnerships.

    Published on 2/5/2015
  • Strategy: PD-1 matchmaking

    Courting combinations with PD-1

    A host of new targets in the tumor microenvironment could lead to combo therapies that turbo-boost PD-1 mAbs and expand their use, but matching targets and tumors will be the next challenge.

    Published on 1/29/2015
  • Figure: A cohort of co-inhibitors

    PD-1 matchmaking Strategy A cohort of co-inhibitors T cells in the tumor microenvironment express a range of co-inhibitor — or checkpoint — proteins that suppress T cell activity and block their antitumor effects. …

    Published on 1/29/2015
  • Table: Co-inhibitory and co-stimulatory targets

    PD-1 matchmaking Strategy Co-inhibitory and co-stimulatory targets Therapeutics targeting new co-inhibitory and co-stimulatory targets being explored as monotherapies or in combination with other co-inhibitory …

    Published on 1/29/2015
  • Strategy: Plenty of CRISPR pie

    Complex CRISPR IP may have little impact on therapeutic development

    The long term winners in the CRISPR space may have little to do with the impending IP brawl over the technology's inventorship

    Published on 1/8/2015
  • The White Space Race

    How Atlas approaches uncharted scientific territory

    Atlas' Jean-Francois Formela thinks successful white space investments require diving into the science and using IP to prevent fast followers.

    Published on 1/8/2015
  • Figure: CRISPR burst

    Plenty of CRISPR pie Strategy CRISPR burst A burst of patent applications in 2014 and dramatic rise in publications related to therapeutic use of CRISPR has followed the publication in 2012 and early 2013 of the …

    Published on 1/8/2015
  • Translational balance

    Panel says academic-to-industry translation requires multifactorial balance

    Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference.

    Published on 12/18/2014
  • Translational balance

    Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference.

    Published on 12/18/2014
  • Incubating innovation

    Two years ago, Janssen formed an internal incubator to solve a key problem: managing discoveries outside its own therapeutic areas. Incubator heads recently talked with SciBX about its progress so far.

    Published on 12/4/2014
  • Merck Encycles through Canada

    The first disclosed grant under Merck's 2013 initiative to fund Canadian innovation will support lead optimization of Encycle Therapeutics' macrocycle program for IBD.

    Published on 12/4/2014
  • Mixing it up at Karolinska

    Karolinska's new deputy vice chancellor, Alexander von Gabain, has plans to break down silos and breed new mindsets to maximize the institute's translational potential.

    Published on 11/20/2014
  • ACTing for NIH

    A new campaign to petition Congress to increase NIH funding has the backing of several academic heavyweights but stops short of defining how the money would be spent.

    Published on 11/6/2014
  • Bayer's Bay Area formula

    Bayer is emphasizing alliances rather than money to tap into Bay Area innovation.

    Published on 10/30/2014
  • The ALS bucket brigade

    The ALS Association is allocating the first funds from its ice bucket challenge to create four new research alliances that focus on genetics and biomarkers for the disease.

    Published on 10/30/2014
  • New CAR shopping

    Kite Pharma's Arie Belldegrun says that target selection is the most important and difficult aspect of early stage CAR T cell research.

    Published on 10/16/2014
  • Figure 1: New kinase inhibitors approved in U.S. by year

    Translational Notes: A conversation with Jeffrey Settleman Figure 1. New kinase inhibitors approved in U.S. by year. Counts for 2014 exclude Chugai Pharmaceutical Co. Ltd.'s Alecensa alectinib, a small molecule …

    Published on 10/2/2014
  • Table 1: Piloting progress in MS

    Translational Notes: Progressive thinking in MS Table 1. Piloting progress in MS. In the first stage of a 5-year initiative, the International Progressive MS Alliance has awarded approximately €75,000 ($95,640) to …

    Published on 10/2/2014
  • A conversation with Jeffrey Settleman

    SciBX spoke with Genentech's Jeffrey Settleman about resistance mechanisms against kinase inhibitors used to treat cancer and what should be done to tackle the problem.

    Published on 10/2/2014
  • Progressive thinking in MS

    The International Progressive MS Alliance is pushing for advances in progressive MS-an understudied form of the disease-by funding 22 projects in the pilot phase of its 5-year, €22 million ($28 million) initiative.

    Published on 10/2/2014
  • Canadian accelerant

    Two Canadian venture firms and a government-funded program have launched Canada's first national health science accelerator, Accel-Rx, to reignite local VC interest in funding early stage biotechs.

    Published on 9/25/2014

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993